Children suffering from a form of autism called ADNP syndrome may benefit from an experimental drug designed to treat Alzheimer's disease.
Genomic autism-related ADNP mutations were found in postmortem olfactory bulbs and hippocampi of Alzheimer's patients.
A new study reports researchers have discovered a new molecular target which is essential for neuroplasticity.
Inhibition of a basic cellular process could contribute to schizophrenia, a new study reports.
Researchers develop a protein called NAP which protects and restores nerve cell communication in some neurodegenerative diseases.
